VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer
Egile Nagusiak: | , , , , , , , , , , , , , , |
---|---|
Formatua: | Conference item |
Argitaratua: |
American Society of Clinical Oncology
2018
|
Gaia: |
---|